About Timi3 Systems
Timi3 Systems, Inc., a biotechnology company, develops a non-invasive transcutaneous ultrasound system for the treatment of patients experiencing an acute myocardial infarction or heart attack. The company specializes in the non-invasive delivery of thrombolytic drugs that hasten the dissolution of thrombus during a myocardial infarction. Timi3 Systems, Inc. was founded in 1999 and is based in Santa Clara, California.
Timi3 Systems Frequently Asked Questions (FAQ)
When was Timi3 Systems founded?
Timi3 Systems was founded in 1999.
Where is Timi3 Systems's headquarters?
Timi3 Systems's headquarters is located at 3032 Coronado Drive, Santa Clara.
What is Timi3 Systems's latest funding round?
Timi3 Systems's latest funding round is Unattributed VC - IV.
How much did Timi3 Systems raise?
Timi3 Systems raised a total of $16.36M.
Who are the investors of Timi3 Systems?
Investors of Timi3 Systems include Venrock and U.S. Venture Partners.
Who are Timi3 Systems's competitors?
Competitors of Timi3 Systems include Longevica, Molmed, Cellerant Therapeutics, Asmacure, Transave and 7 more.
Compare Timi3 Systems to Competitors
Longevica is a biotechnology that is researching mechanisms of healthy aging and life extension. The company is also developing an open research tool for scientists and research institutions to access a data set that tracks the effects of pharmacological compounds for testing drugs.
Nuvelo, Inc. is dedicated to improving the lives of patients through the discovery, development and commercialization of novel drugs for acute cardiovascular and cancer therapy. Nuvelo's development pipeline includes alfimeprase, a direct-acting fibrinolytic for the treatment of thrombotic- related disorders including acute ischemic stroke and catheter occlusion and preclinical candidates NU206 for the potential treatment of chemotherapy/radiation therapy-induced mucositis and inflammatory bowel disease and NU172, a direct thrombin inhibitor for use as a short-acting anticoagulant during medical or surgical procedures. In addition, Nuvelo expects to leverage its expertise in cancer antibody discovery to further expand its pipeline and create additional partnering and licensing opportunities.
Cellerant Therapeutics is a clinical stage biotechnology company focused on the regulation of the hematopoietic (blood-forming) system. The Company is developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant's lead product, CLT-008 is currently in two Phase 1 clinical trials in patients with hematological malignancies. The Company also has a Cancer Stem Cell (CSC) antibody discovery program focused on therapies for acute myeloid leukemia, multiple myeloma and myelodysplastic syndrome.
Checkpoint Surgical is a medical device company focused on advancing peripheral nerve care. The company offers a range of nerve care products, including nerve stimulators and biomaterials for nerve repair, as well as educational programs for surgeons. Checkpoint Surgical primarily serves the healthcare sector, with a focus on surgical and medical device industries. It was founded in 2009 and is based in Beachwood, Ohio.
Solixia is a biotechnology company dedicated to helping cancer patients through the use of nanoparticle technology.
Anaborex Anaborex is an early stage biotechnology company developing drugs for the treatment of the wasting syndrome many cancer patients experience towards the late stages of their disease.